Immune cells for advanced GIST
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a personalized cell therapy that uses your own immune cells (called TIL) to fight GIST. The cells are grown in the lab and given back to you along with a drug called interleukin-2 to boost your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your GIST has spread or cannot be removed with surgery, and standard treatments (like imatinib or sunitinib) either stopped working or you couldn't take them.
- You must have a companion cell harvest protocol to make TIL cells from your tumor.
- You are between 18 and 75 years old.
- You are healthy enough to have a good performance status (ECOG 0-1) and expected to live more than 3 months.
- Your blood counts and liver and kidney function meet certain minimum levels.
- You haven't had any serious immune system problems or active infections, and you're not on steroid therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This study looks at why some GIST tumors stop responding to standard treatments. It uses special imaging and genetic testing of tumor tissue to find resistance patterns, which may guide future treatment choices.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
Hear when a new Locally Advanced Gastrointestinal Stromal Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.